NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Sutro Biopharma, Inc. STRO
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$102.5M
▲ 65.2% vs FY2024
EPS · FY25
$-22.49
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-186.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 102.5M
Revenue, FY2025 · full 10-year series below
Revenue
Net income
The company lost 186 cents on every revenue dollar this year.
Per share
USD -22.49
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-154.5%
Net margin-186.5%
Return on assets-68.1%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+19.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+14.8%
+19.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 173.8M
total assets, end of FY2025
Total assetsUSD 173.8M
EquityUSD -132.5M
CashUSD 58.1M
Current ratio2.01×
Equity funds -76% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.1
0.1
0.2
0.1
0.1
0.0
0.0
0.0
0.1
0.1
Operating income $B
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
0.0
EBITDA $B
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
0.0
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
0.0
EPS, diluted $
−22.49
−29.40
−1.78
−2.35
−2.29
−0.99
−2.43
−6.13
−43.95
0.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
·
−234.2
−58.2
−50.8
−36.1
−14.9
−104.0
−313.4
·
·
Shares out B
0.01
0.01
0.06
0.06
0.05
0.05
0.02
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed